{"id":"sequential-and-maintenance-icotinib","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Rash/dermatitis"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Elevated liver enzymes"},{"rate":"10-20","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2087361","moleculeType":"Small molecule","molecularWeight":"391.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Icotinib irreversibly inhibits EGFR tyrosine kinase activity, preventing downstream signaling cascades that drive cell growth and survival in EGFR-dependent cancers. The sequential and maintenance dosing regimen is designed to optimize therapeutic efficacy while managing tolerability in patients with EGFR-mutant non-small cell lung cancer.","oneSentence":"Icotinib is a small-molecule tyrosine kinase inhibitor that selectively blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:07:25.617Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC) with EGFR mutations"}]},"trialDetails":[{"nctId":"NCT02103257","phase":"PHASE4","title":"Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-03","conditions":"EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma","enrollment":192},{"nctId":"NCT02194556","phase":"PHASE4","title":"Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-07","conditions":"EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gemzar","DDP","Comana, BPI-2009"],"phase":"marketed","status":"active","brandName":"Sequential and maintenance icotinib","genericName":"Sequential and maintenance icotinib","companyName":"Betta Pharmaceuticals Co., Ltd.","companyId":"betta-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Icotinib is a small-molecule tyrosine kinase inhibitor that selectively blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation. Used for Non-small cell lung cancer (NSCLC) with EGFR mutations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}